Aquestive Therapeutics is a specialty pharmaceutical company with two businesses: a contract manufacturing operation that generates current revenue, and a pipeline focused on orally administered alternatives to injectable therapies. The manufacturing business produces oral film products at Aquestive's Indiana facilities for licensees who handle commercialization. The dominant manufactured product is Suboxone, a buprenorphine/naloxone sublingual film for opioid dependence that Indivior markets — Aquestive is Suboxone's sole manufacturer and earns fees tied to production volumes. Other licensed products include Sympazan (clobazam film for epilepsy), Ondif (ondansetron film for nausea), and Emylif (riluzole film for ALS). This manufacturing base is structurally declining as Suboxone loses branded share to generics. The lead pipeline asset is Anaphylm, a sublingual film formulation of an epinephrine prodrug for emergency treatment of anaphylaxis. Designed to dissolve under the tongue without a needle, Anaphylm is small enough to carry on the back of a phone or in a wallet — Aquestive's core pitch is that the format solves the carry-rate problem that auto-injectors haven't. The FDA issued a Complete Response Letter in January 2026 over human factors issues with pouch opening and film placement, not clinical efficacy, and Aquestive plans to resubmit in Q3 2026. If approved, Aquestive plans to commercialize Anaphylm directly in the U.S. with a specialty sales force targeting allergists, and out-license the product internationally.